News

Janus kinase (JAK) inhibitors are the newest class of drugs used to treat rheumatoid arthritis. How much do you know about these drugs? Test your knowledge with this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 19, 2021.

Eric Morand, MD, discusses “Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials.”

The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss.

The relationship between depression and medical errors is bidirectional, meaning depressive symptoms may lead to more medical errors in practice and medical errors may lead to the development of or worsened depressive symptoms. In other words, physician well-being is critical to patient care.

In a recent workforce survey of more than 12,000 physicians across 29+ specialties, 50% of rheumatologists reported significant burnout or depression, making rheumatology the second-highest ranking field for burnout (after critical care).

Rheumatoid arthritis is a complex condition. How much do you know about RA treatment?

Continual improvement was shown in patient-reported pain levels when treated with guselkumab compared with placebo.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 12, 2021.

While statin initiation was associated with reducing the risk of cardiovascular disease, it may increase in the risk of developing diabetes in patients with rheumatoid arthritis.

An interview on new findings suggesting baseline heart failure may be an indicator of increased mortality risk in patients treating arthritis with the DMARD.

A team from Vanderbilt identified 4 key predictors from a retrospective analysis of cases since 2020.

New late-breaking data from ACR 2021 show the mRNA vaccine may differ in patients dependent on their disease.

Patients who are treated with B cell depletion therapies show that their B cell count at time of vaccination can impact their COVID-19 antibody response.

Investigators observed stark contrasts in COVID-19 mRNA vaccination response among inflammatory rheumatic disease patients and the general population.

An assessment of a rheumatic disease cohort shows Spike protein antibody response is significantly decreased in vaccinated patients, and may vary by treatment.

Patients are increasingly encouraged to take an active role in the management of their chronic conditions. How much do you know about self-management in rheumatoid arthritis?

Fetal deaths associated with the rheumatic disease have been on the decline, but increased risks persist nonetheless.

Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.

Kyriakos A. Kirou, MD, DSc, FACP, explains the key findings of his upcoming ACR presentation, “COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine.”

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

"The primary efficacy endpoint was the proportion of patients with disease control without other immunosuppressants and prednisone-equivalent dose of ≤5 mg/day at week 52," Aranow stated.

Interim data from a post-marketing analysis suggest a boxed label warning for the drug in 2019 may have limited high-risk patients taking the biologic therapy.

A cross-sectional analysis suggests patients with worse social risk scores are significantly more likely to be impacted by juvenile idiopathic arthritis.

More data from ACR 2021 evidences the risk of minimal response to mRNA vaccines in autoimmune disorder patients on rituximab.

The oral selective inhibitor showed significant benefit versus placebo at 2 different doses in the phase 2b trial.

A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.

New phase 3 data show TX-102 SL from Tonix may benefit central sensitization in patients afflicted with fibromyalgia pain.

A pandemic-era study suggests rheumatology care teams can capably provide beneficial care via telemedicine to treatment-stable patients.

New ACR findings suggest patients taking the common biologic drug closely leading up to their vaccination may not have a humoral response to it.